NCT06087419View on ClinicalTrials.gov

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

chidamide

30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)

DRUG

Venetoclax Oral Tablet

400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)

DRUG

Inotuzumab Ozogamicin

0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06087419 - A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | Biotech Hunter | Biotech Hunter